Mammary metaplastic squamous cell carcinoma: a case report.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: high-risk mammary metaplastic squamous cell carcinoma observed here warrants further investigation
I · Intervention 중재 / 시술
neoadjuvant chemotherapy with a nab-paclitaxel, epirubicin, cyclophosphamide regimen
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
It underscores the need for heightened clinical vigilance. The potential benefit of adjuvant capecitabine for patients with high-risk mammary metaplastic squamous cell carcinoma observed here warrants further investigation.
[BACKGROUND] Mammary metaplastic squamous cell carcinoma is an exceptionally rare and aggressive triple-negative breast cancer.
APA
Tianqing Y, Guoliang Z, et al. (2026). Mammary metaplastic squamous cell carcinoma: a case report.. Journal of medical case reports, 20(1). https://doi.org/10.1186/s13256-025-05818-7
MLA
Tianqing Y, et al.. "Mammary metaplastic squamous cell carcinoma: a case report.." Journal of medical case reports, vol. 20, no. 1, 2026.
PMID
41654984
Abstract
[BACKGROUND] Mammary metaplastic squamous cell carcinoma is an exceptionally rare and aggressive triple-negative breast cancer. Its propensity to mimic benign breast abscesses poses a significant diagnostic challenge, often leading to treatment delays.
[CASE PRESENTATION] A 41-year-old Asian woman presented with a rapidly enlarging right breast mass, initially misdiagnosed and treated as an abscess at a local hospital. Definitive biopsy revealed triple-negative mammary metaplastic squamous cell carcinoma. The patient received neoadjuvant chemotherapy with a nab-paclitaxel, epirubicin, cyclophosphamide regimen. After an initial partial response observed in the first five cycles, the tumor exhibited progressive disease following the sixth cycle, a phenomenon potentially indicative of acquired chemoresistance. The patient subsequently underwent a modified radical mastectomy. Given the high-risk features and inspired by the SYSUCC-001 trial, adjuvant dose-dense capecitabine was administered postoperatively. No recurrence was detected during follow-up.
[CONCLUSION] This case highlights a classic diagnostic pitfall of mammary metaplastic squamous cell carcinoma masquerading as an abscess and illustrates a unique pattern of acquired resistance to a standard taxane-anthracycline neoadjuvant chemotherapy regimen. It underscores the need for heightened clinical vigilance. The potential benefit of adjuvant capecitabine for patients with high-risk mammary metaplastic squamous cell carcinoma observed here warrants further investigation.
[CASE PRESENTATION] A 41-year-old Asian woman presented with a rapidly enlarging right breast mass, initially misdiagnosed and treated as an abscess at a local hospital. Definitive biopsy revealed triple-negative mammary metaplastic squamous cell carcinoma. The patient received neoadjuvant chemotherapy with a nab-paclitaxel, epirubicin, cyclophosphamide regimen. After an initial partial response observed in the first five cycles, the tumor exhibited progressive disease following the sixth cycle, a phenomenon potentially indicative of acquired chemoresistance. The patient subsequently underwent a modified radical mastectomy. Given the high-risk features and inspired by the SYSUCC-001 trial, adjuvant dose-dense capecitabine was administered postoperatively. No recurrence was detected during follow-up.
[CONCLUSION] This case highlights a classic diagnostic pitfall of mammary metaplastic squamous cell carcinoma masquerading as an abscess and illustrates a unique pattern of acquired resistance to a standard taxane-anthracycline neoadjuvant chemotherapy regimen. It underscores the need for heightened clinical vigilance. The potential benefit of adjuvant capecitabine for patients with high-risk mammary metaplastic squamous cell carcinoma observed here warrants further investigation.
MeSH Terms
Humans; Female; Adult; Carcinoma, Squamous Cell; Neoadjuvant Therapy; Triple Negative Breast Neoplasms; Chemotherapy, Adjuvant; Mastectomy, Modified Radical; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diagnosis, Differential; Paclitaxel